Literature DB >> 8354324

Guillain-Barré syndrome following immunisation with Haemophilus influenzae type b conjugate vaccine.

A Gervaix1, M Caflisch, S Suter, C A Haenggeli.   

Abstract

The Guillain-Barré syndrome (GBS) is an immune-mediated disease often associated with viral or bacterial infections and with immunisation. IgM antibodies have been implicated as the main trigger event in GBS. So far, only four cases of GBS have been observed following immunisation with a conjugate vaccine against Haemophilus influenzae type b. We report another patient with GBS after this vaccination. We measured immunoglobulins against the H. influenzae type b polysaccharide (PRP) component of the vaccine. Surprisingly the anti-PRP IgM antibody level was markedly elevated (100 micrograms/ml) in the plasma of this patient. We speculate that an excessive anti-PRP IgM antibody response to the vaccine might be the cause of GBS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354324     DOI: 10.1007/bf01954093

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome.

Authors:  E Shahar; E G Murphy; C M Roifman
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

2.  Haemophilus conjugate vaccine and Guillain-Barré syndrome.

Authors:  T P Gross; S W Hayes
Journal:  J Pediatr       Date:  1991-01       Impact factor: 4.406

Review 3.  Immunological parameters in Guillain-Barré syndrome.

Authors:  D E McFarlin
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

Review 4.  Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barré syndrome.

Authors:  C L Koski
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

5.  Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age.

Authors:  M L Lepow; J S Samuelson; L K Gordon
Journal:  J Pediatr       Date:  1985-02       Impact factor: 4.406

6.  Guillain-Barré syndrome. Clinicoepidemiologic features and effect of influenza vaccine.

Authors:  E Beghi; L T Kurland; D W Mulder; W C Wiederholt
Journal:  Arch Neurol       Date:  1985-11

7.  Criteria for diagnosis of Guillain-Barré syndrome.

Authors: 
Journal:  Ann Neurol       Date:  1978-06       Impact factor: 10.422

8.  Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome) after immunization with Haemophilus influenzae type b conjugate vaccine.

Authors:  O F D'Cruz; E D Shapiro; K N Spiegelman; C R Leicher; G N Breningstall; B O Khatri; W B Dobyns
Journal:  J Pediatr       Date:  1989-11       Impact factor: 4.406

9.  IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside.

Authors:  A A Ilyas; R H Quarles; T D MacIntosh; M J Dobersen; B D Trapp; M C Dalakas; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

  9 in total
  3 in total

Review 1.  Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination.

Authors:  Eitan Israeli; Nancy Agmon-Levin; Miri Blank; Joab Chapman; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 2.  Vaccines and Guillain-Barré syndrome.

Authors:  Penina Haber; James Sejvar; Yann Mikaeloff; Frank DeStefano
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

Review 3.  Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons.

Authors:  Godwin C Enwere; Gandhali Paranjape; Prasad S Kulkarni; Manisha Ginde; Katharina Hartmann; Simonetta Viviani; Julie Chaumont; Lionel Martellet; Marie-Francoise Makadi; Karen Ivinson; Elisa Marchetti; Jacques Herve; Kim Kertson; F Marc LaForce; Marie-Pierre Preziosi
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.